Estradiol + Drospirenone (Angeliq): The Definitive Guide

What is Angeliq?

Angeliq is an oral menopausal combination of estradiol and drospirenone. Estradiol supplies estrogen for symptom treatment; drospirenone is a synthetic progestin that opposes the uterine-lining effect within the complete continuous regimen. It is not estrogen-only, micronized progesterone or a birth-control pill. [1], [2]

The US brand has two selected strength pairs, while the checked UK tablet contains a different drospirenone amount. The same brand name therefore does not establish one universal formula. Kidney contraindications and storage instructions also differ by country. This guide keeps each complete label together rather than picking a dose from one and precautions from another. [1], [2]

Verification is bounded to those full US and UK labels. It does not establish global stock, reimbursement or availability in every country. Contraceptives containing drospirenone with ethinyl estradiol or estetrol are separate products with different populations and calendars; their reviews and approvals cannot replace Angeliq evidence. [1], [2]

Which exact doses and calendars are verified?

The US hot-flash starting instruction uses drospirenone 0.25 mg/estradiol 0.5 mg, with response-guided adjustment. The US 0.5 mg/1 mg pair also has a vasomotor indication and is the named vaginal-atrophy instruction. The UK product instead lists estradiol first: 1 mg estradiol/2 mg drospirenone. Check component order as well as each number. [1], [2]

The complete regimen is continuous. Do not add the inert days of a drospirenone contraceptive or attach a sequential progesterone calendar to this fixed tablet. Higher or added estrogen creates a new uterine-protection question; the included progestin is not unlimited protection for any external estrogen amount. Prescribing should define the whole plan. [1], [2], [3]

Evidence note: each row comes from its full named country label, not a mixed global dosing range. No equivalence to another estrogen/progestogen is assumed.

What can the complete combination treat?

The labels support menopausal estrogen-deficiency symptoms, particularly moderate-to-severe hot flashes under the US indications. Fewer night sweats may improve interrupted sleep, but this is not a general treatment for all anxiety, fatigue or low mood. Define the symptom and degree of improvement needed to justify treatment. [1], [2], [3]

For isolated vaginal symptoms, the US label says to consider topical vaginal therapy. Systemic treatment can leave some GSM symptoms unresolved, and urinary pain, discharge or bleeding may have another cause. UK Angeliq also has an osteoporosis-prevention indication limited to high fracture risk with intolerance or contraindication to other approved preventive medicines. Do not extend that country indication or dose to every US product. [1], [2]

Drospirenone’s fluid-regulating and antiandrogenic properties do not make Angeliq a guaranteed weight-loss, hair-restoration or libido treatment. Selected users can feel better without those outcomes being approved indications or reliable expectations. Mechanism alone cannot establish personal benefit. [1], [2], [5]

How should missed tablets and switches be handled?

Swallow the complete oral tablet at the regular time under the country leaflet. UK Angeliq says take a forgotten tablet promptly but no extra tablet after more than 24 hours; several missed doses can cause bleeding. The US patient leaflet instead says skip when the next dose is almost due and not to take two together. Keep those instructions separate. [1], [2]

For a UK switch from cyclic or sequential combined HRT, treatment starts the day after completing the previous regimen. Do not borrow Kliovance’s withdrawal-bleed-based instruction or a contraceptive’s pack-start rule. A planned switch should name the previous and new medicines, when each stops/starts and how ongoing uterine protection is maintained. [2], [3]

What do symptom and endometrial studies establish?

Angeliq’s complete-formulation studies assess symptom relief, endometrial findings and bleeding. The progestin’s contribution matters because unopposed systemic estrogen stimulates the lining. Those studies support the named combined regimen; they do not establish protection for every estrogen-plus-drospirenone prescription or show superiority over separate progesterone. [1], [2]

Class precautions in the label discuss WHI’s CEE/medroxyprogesterone trials. Angeliq was not directly compared with modern patches in those trials. Do not assign WHI rates as precise Angeliq-specific risks or treat a favorable fluid/blood-pressure biomarker as proof of fewer clinical heart attacks. Long-term clinical comparisons and symptom efficacy answer different questions. [1], [2], [3]

Which kidney, potassium and other risks matter?

Drospirenone can raise potassium through anti-mineralocorticoid activity. US Angeliq contraindicates renal impairment, hepatic impairment and adrenal insufficiency. The UK SmPC instead specifies severe renal insufficiency or acute renal failure and severe hepatic disease, with supervision for other impairment contexts. A real country difference should be resolved by the prescriber using the actual medicine, not by self-selecting a foreign rule. [1], [2]

Review potassium-raising medicines, including supplements, potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers and regular NSAIDs. Strong CYP3A4 inhibitors can increase exposure; enzyme inducers can change effects or bleeding. Blood-pressure or thyroid-treatment issues may require specific review. This is not an assurance of no interactions because the tablet is called low dose. [1], [2]

The labels also contraindicate relevant cancer, unexplained bleeding, current/previous venous clots or arterial thromboembolic disease and other specified conditions. Breast discomfort, headache, nausea, bleeding and mood symptoms can occur. Sudden chest pain, breathlessness, a painful swollen leg, weakness, speech or visual change requires urgent assessment; jaundice or a new severe headache needs prompt advice. [1], [2]

The retrieved US revision remains December 2023; UK text is April 2026. FDA’s first six MHT revisions do not prove an Angeliq update or elimination of these risks. [1], [2], [4]

Who needs potassium checks and how is bleeding reviewed?

US Angeliq advises caution with potassium-raising medicines and considering potassium monitoring during the first month in high-risk people taking strong CYP3A4 inhibitors long-term. UK Angeliq recommends a first-month check in its specified renal/upper-reference-range potassium context, especially with potassium-sparing medicines. These are different risk-directed statements, not one universal monthly laboratory rule. [1], [2]

NICE recommends a three-month treatment review then annual review, sooner for difficulties. Record both component amounts, adherence, symptoms, blood pressure concerns, bleeding and adverse effects. Persistent unscheduled systemic-HRT bleeding beyond six months after start or three months after change needs prompt assessment; heavy or otherwise concerning bleeding may need earlier assessment. Included progestin does not make routine ultrasound a substitute for evaluating a new problem. [1], [2], [3]

How should a stop or switch be planned?

NICE allows gradual reduction or immediate stopping of MHT. A fixed tablet changes both hormones together, and hot flashes or other symptoms can return. Do not improvise a taper by treating a differently formulated foreign tablet as equivalent. Discuss the reason for stopping, symptom recurrence and whether local vaginal treatment should continue. [1], [2], [3]

If systemic estrogen continues under a new product, explicitly maintain appropriate uterine protection. A switch to separate estradiol and progesterone, or to another combination, requires its own route and calendar. MHT does not supply a contraceptive plan. Serious suspected reactions require prompt assessment instead of a routine medication experiment. [1], [2], [3]

What are the actual country storage rules?

US Angeliq is stored at 20–25°C, with excursions permitted to 15–30°C. The checked UK product requires no special storage conditions. Keep its supplied package and expiry and ask a pharmacist about heat, damage or an uncertain import. The US excursion range is not an instruction added to the UK SmPC, nor an ideal ongoing storage temperature. [1], [2]

How does it compare with other complete MHT regimens?

Angeliq offers continuous oral estrogen and progestin in one tablet. Activella uses a different progestin; Bijuva uses progesterone; separate components can allow transdermal estradiol and a different protection schedule. Compare whole regimens rather than rank progestins by a nickname or match milligrams. Route, kidney/potassium constraints, bleeding, tolerability and practicality can change the choice. [1], [2], [3]

A clinician may prefer a transdermal estrogen route in some clot-risk contexts. That is a different regimen, not an Angeliq tablet applied to skin or a guarantee of no systemic contraindications. Adding external estrogen or borrowing a drospirenone contraceptive changes the evidence question. A convenient fixed tablet is useful only when the complete plan fits the person. [1], [2], [3]

What do freshly retrieved Angeliq accounts describe?

The public page describes perceived hot-flash, night-sweat and comfort improvement and preference for continuing, alongside ongoing or worsened symptoms, breast discomfort and weight concerns. The page includes different countries and older accounts; it cannot establish current local supply or the effect of one exact strength for everyone. [5]

We omit identities, ratings, amounts and timelines. A favorable hair, mood or weight story is not a new approved indication. A historical statement about UK discontinuation is not a current regulatory conclusion: this guide uses the retrieved April 2026 UK SmPC. Bring the actual package and symptom pattern to the review rather than copy an anecdotal product switch. [1], [2], [5]

Common questions about Angeliq

Is UK Angeliq the same strength as the US brand?

No. The checked UK tablet contains estradiol 1 mg/drospirenone 2 mg; selected US drospirenone amounts are 0.25 or 0.5 mg. [1], [2] The estrogen amount and local indication also belong to the complete country product. Do not derive a tablet count by matching one component or transfer another country’s missed-dose rule. Ask the pharmacy to identify the actual pack and prescriber to confirm any change. See the country-specific protocol. [1], [2]

Does the included progestin protect any added estrogen?

Its evidence belongs to the complete labeled regimen. Additional systemic estrogen needs a new protection assessment. [1], [2], [3] Adding another systemic estrogen changes the question from the tested fixed combination to a different regimen. Persistent symptoms should prompt review of the cause, adherence and appropriate alternatives rather than a presumed protected increase. Keep the exact products in that conversation. See evidence and its boundaries. [1], [2], [3]

Is everyone supposed to check potassium monthly?

No. The labels give risk-directed first-month advice with different country wording. [1], [2] Potassium-raising medicines, renal circumstances and specific interacting treatments affect which instructions apply. A universal repeated test schedule would obscure those distinctions. Bring all prescriptions and supplements to the review and ask why a test is recommended for you. See the country-specific monitoring discussion. [1], [2] The country-specific exclusions still need to be considered.

Are kidney restrictions identical in both countries?

No. US renal impairment is contraindicated; the UK wording specifies severe renal insufficiency/acute failure and monitoring contexts. Use the actual local label with the prescriber. [1], [2] Do not interpret the difference as permission to use the product with a contraindication or proof that a normal potassium result removes renal concerns. Suitability requires the local complete label and clinical assessment, including medicines that may raise potassium. See kidney and interaction risks. [1], [2]

Can I use contraceptive inert days?

No. The checked Angeliq regimen is continuous menopausal treatment, not a contraceptive calendar. [1], [2] A contraceptive pack and a menopausal fixed combination have different goals, component amounts and calendars. Changing the exposure pattern may also change uterine opposition. Ask about a planned stop or switch rather than insert days from another box, even if both contain drospirenone. See daily use. [1], [2] Describe the complete medication list.

Does it guarantee weight loss or better hair?

No. Pharmacology and individual accounts do not establish those outcomes as reliable benefits. [1], [2], [5] Anti-mineralocorticoid and anti-androgenic actions are pharmacology, not a guarantee that every person loses weight or notices a hair benefit. Mixed public reports cannot supply that prediction or isolate the cause of an effect. Review the approved goal and unwanted effects instead. See public reports and their limits. [1], [2], [5]

Did the first 2026 FDA revisions update Angeliq?

That was not verified. The retrieved US full label remains revised December 2023. [1], [4] Confirm the actual country product and latest package text before using an announcement to guide a decision. Contraindications and ordinary warnings remain relevant even when regulatory language changes elsewhere. Product approval, label revision and clinical suitability answer different questions. See risks and current label scope. [1], [4] Keep the missed dose recorded.

Glossary

Definitions for interpreting the product, calendar and limitations.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Fixed combination

One dosage form contains both hormones; changing it changes both components.

Estradiol

The estrogen in these named menopause combinations.

Drospirenone

A synthetic progestin with potassium-relevant anti-mineralocorticoid activity.

CYP3A4

A metabolic enzyme affected by inducing or inhibiting medicines.

Hyperkalemia

High blood potassium; a particular safety issue with drospirenone.

How was this guide researched?

Named full labels define calendars, indications and risks. Marketing records do not prove stock; guidelines inform care without changing authorization. Public accounts remain separate from clinical evidence. Sources identify document revision and access.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides